🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

442 results for “Institut” Clear

  1. Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® MR) in Healthy Participants under Fed Conditions.

    The George Institute

    No medical condicion.

    phase 1 other active

    1 trial

  2. NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophagogastric adenocarcinoma

    The George Institute

    resectable esophagogastric adenocarcinoma

    phase 1 other active

    1 trial

  3. OPB-31121

    Otsuka Beijing Research Institute

    Non-Hodgkin's Lymphoma(NHL)

    phase 1 small molecule completed

    1 trial

  4. OPC-108459

    Otsuka Beijing Research Institute

    Atrial Fibrillation

    phase 1 small molecule completed

    1 trial

  5. Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).

    The George Institute

    Non-small cell lung cancer (NSCLC)

    phase 1 other active

    1 trial

  6. Phase I single-blind clinical trial to evaluate the safety and local immune activation of a toll-like receptor 5 agonist (FLAMOD) administered by aerosol

    The George Institute

    Pneumonia

    phase 1 other active

    1 trial

  7. Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

  8. Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

  9. Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT.

    The George Institute

    graft-versus-host disease

    phase 1 other active

    1 trial

  10. Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT.

    The George Institute

    graft-versus-host disease

    phase 1 other active

    1 trial

  11. Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg Under Fasting Conditions, and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg Under Fasting versus Fed Conditions.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  12. Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis.

    The George Institute

    Idiopathic Pulmonary Fibrosis

    phase 1 other active

    1 trial

  13. Tolvaptan 15mg or 30mg or 60mg or Placebo

    Otsuka Beijing Research Institute

    Healthy

    phase 1 small molecule completed

    1 trial

  14. Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs).

    The George Institute

    advanced or metastasic triple-negative breast cancer

    phase 1 other active

    1 trial

  15. clinical trial to determine the feasibility and safety of the mesenchymal stem cells use in women over 50 years of age with urinary incontinencee

    The George Institute

    Stress or mixed urinary incontinence in women over 50 years of age not responding to conventional treatments

    phase 1 other active

    1 trial

  16. „INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors

    The George Institute

    Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)

    phase 1 other active

    1 trial

  17. -

    The George Institute

    Acute lower Respiratory Tract Infection or acute rhinosinusitis

    approved small molecule active

    1 trial

  18. ACETYLSALICYLIC ACID

    The George Institute

    Obstetrics – Preeclampsia

    approved small molecule active

    1 trial

  19. ALUTARD SQ epitel, injektionsvätska, suspension - 553 Hund, Livostin 0,5 mg/ml ögondroppar, suspension, Desloratadine Sandoz 5 mg filmdragerade tabletter, Nasonex 50 mikrogram/dos nässpray, suspension

    The George Institute

    Allergic rhinitis due to dog allergy

    approved small molecule active

    1 trial

  20. AMOXICILINA NORMON 1000 mg Comprimidos EFG

    The George Institute

    Infective endocarditis

    approved small molecule active

    1 trial

  21. ASS-ratiopharm® 100 mg TAH Tabletten, Xarelto 15 mg film-coated tablets

    The George Institute

    Risk of stroke by Atrial Fibrillation

    approved small molecule active

    1 trial

  22. Adrenalina B. Braun 1 mg/ml Solución Inyectable, Ropivacaína B. Braun 2 mg/ml solución inyectable y para perfusión EFG

    The George Institute

    Knee Osteoarthritis

    approved small molecule active

    1 trial

  23. Alirocumab, Placebo product for REGN727

    The George Institute

    Cardiac allograft vaculopathy in recent heart transplant recipients

    approved small molecule active

    1 trial

  24. Amiodarone hydrochloride 200 mg tablets

    The George Institute

    Persistent atrial fibrillation

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources